Effect of the angiotensin II receptor antagonist valsartan on lipid profile and glucose metabolism in patients with hypertension.

What Was Tested

The paper reports a study of Tetrazoles, published as a randomized controlled trial.

The present trial evaluated the effect of the angiotensin II receptor antagonist, valsartan, on the lipid profile and glucose metabolism in patients with mild-to-moderate hypertension.

In the placebo group, the corresponding values were 7.8 +/- 14.9 mmHg and 6.2 +/- 7.3 mmHg, respectively.

Who Took Part

According to the abstract, 123 patients were involved.

By PubMed's age tags, the people studied were adults, middle-aged adults and older adults, both men and women.

A total of 123 patients were randomized, of whom 112 patients completed the study.

How the Study Was Run

The researchers set it up as a randomized, double-blind, placebo-controlled and multicenter study.

Random assignment meant chance, not the researchers, decided who got Tetrazoles and who got the comparison, which limits bias.

As a double-blind Tetrazoles study, the assignments were hidden from both participants and investigators until the end.

Some patients received a placebo instead of Tetrazoles, giving a reference point.

Running at several centres spread the Tetrazoles study over different clinics and patient groups.

What Was Measured

The present trial evaluated the effect of the angiotensin II receptor antagonist, valsartan, on the lipid profile and glucose metabolism in patients with mild-to-moderate hypertension.

Topics PubMed links to this paper include Angiotensin Receptor Antagonists, Blood Glucose, Cholesterol, Cholesterol, LDL, Hypertension, Lipids and Safety.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Tetrazoles in 123 patients.

The publication is from 2002 (The Journal of international medical research), a journal based in England.

More context: all human trials.